Comparing the current results to its competitors, Kymera Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 55.5 % year on year. The sales growth was above Kymera Therapeutics Inc 's competitors' average revenue growth of 8.85 %, achieved in the same quarter.
Kymera Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 35.93 %
Kymera Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape includes larger pharmaceutical companies, biotechnology firms, and academic institutions. Companies developing small molecule protein degrader therapies include Arvinas, Inc., C4 Therapeutics, Inc., Nurix Therapeutics, Inc., and Foghorn Therapeutics, Inc. Several pharmaceutical companies have disclosed preclinical investments in this area. Competition also arises from entities developing other targeted protein degradation methods, as well as small molecule, antibody, or gene therapies for similar indications. For programs targeting STAT6, competitors include Gilead Sciences, Inc., Johnson & Johnson, Pfizer, and Sanofi, which have announced partnerships or maintain internal programs. Many targeted indications have approved standards of care involving traditional therapeutic modalities, necessitating demonstration of favorable profiles for protein degrader therapies. The company protects its proprietary technology and competitive position through patents, trade secrets, confidentiality agreements, and invention assignment agreements. Orphan drug exclusivity may affect competition by preventing approval of similar therapeutic agents for seven years unless clinical superiority is demonstrated.
May 14, 2024
Kymera Therapeutics, a renowned biopharmaceutical company focused on developing novel targeted therapies, has recently unveiled groundbreaking clinical data from ongoing trials. These studies involve the investigational drugs STAT3 Degrader KT-333 and IRAK4 Degrader KT-474, showcasing their potential to revolutionize the treatment landscape for various challenging diseases. The presented findings open new avenues for advanced therapeutic interventions, providing hope for patients and reinforcing Kymera Therapeutics position as a leading innovator in precision medicine.Clinical Data on STAT3 Degrader KT-333:In an abstract released today, Kymera Therapeutics divulged essential safety, pharmacodynamic, and cli...
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Moonlake Immunotherapeutics's business model revolves around the development and commercialization of innovative immunotherapies for the treatment of diseases.
Sources:
Kymera Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kymera Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
